Evidence map›Paper›PMID 32457241›Full record

ArticlemBio2020

The HIV-1 Env gp120 Inner Domain Shapes the Phe43 Cavity and the CD4 Binding Site.

Jérémie Prévost, William D Tolbert, Halima Medjahed, Rebekah T Sherburn, Navid Madani, Daria Zoubchenok, Gabrielle Gendron-Lepage, Althea E Gaffney, Melissa C Grenier, Sharon Kirk and 14 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Stronger binding affinities ofInfectious Disease Modelling · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 9 institutions in 3 countries.

Jérémie PrévostCentre de Recherche du CHUM, Montreal, Quebec, Canada.
William D TolbertInfectious Diseases Division, Department of Medicine of Uniformed Services, University of the Health Sciences, Bethesda, Maryland, USA.
Halima MedjahedCentre de Recherche du CHUM, Montreal, Quebec, Canada.
Rebekah T SherburnInfectious Diseases Division, Department of Medicine of Uniformed Services, University of the Health Sciences, Bethesda, Maryland, USA.
Navid MadaniDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Daria ZoubchenokCentre de Recherche du CHUM, Montreal, Quebec, Canada.
Gabrielle Gendron-LepageCentre de Recherche du CHUM, Montreal, Quebec, Canada.
Althea E GaffneyDepartment of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Melissa C GrenierDepartment of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Sharon KirkDepartment of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Natasha VergaraDepartment of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
Changze HanDepartment of Microbiology, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.
Brendan T MannU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Agnès L ChénineU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Adel AhmedDepartment of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
Irwin ChaikenDepartment of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
Frank KirchhoffInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Beatrice H HahnDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Hillel HaimDepartment of Microbiology, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.
Cameron F AbramsDepartment of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
Amos B SmithDepartment of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Joseph SodroskiDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Marzena PazgierInfectious Diseases Division, Department of Medicine of Uniformed Services, University of the Health Sciences, Bethesda, Maryland, USA.
Andrés FinziCentre de Recherche du CHUM, Montreal, Quebec, Canada andres.finzi@umontreal.ca.
University of Pennsylvania · USCentre Hospitalier de l’Université de Montréal · CADrexel University · USUniformed Services University of the Health Sciences · USDana-Farber Cancer Institute · USHenry M. Jackson Foundation · USUniversity of Iowa · USMcGill University · CAUniversität Ulm · DE

Funding

Virus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Kevin Wiehe · 2017 to 2026
$40.7M
Understanding Envelope Function in HIV-1 Infection: The Design, Synthesis and Validation of Small Molecule HIV-1 Env InhibitorsP01GM056550 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI ABRAMS, CAMERON F · 1997 to 2018
$31.2M
Understanding Envelope Function in HIV-1 Infection: The Design, Synthesis and Validation of Small Molecule HIV-1 Env InhibitorsP01AI150471 · NIAID · DREXEL UNIVERSITY · PI HENDRICKSON, WAYNE A. · 2019 to 2022
$7.8M
Computational models of naturally acquired immunity to falciparum malariaU01AI150741 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BUTTE, ATUL J, GREENHOUSE, BRYAN R · 2020 to 2024
$7.4M
Optimizing glycan shield coverage, germline B cell receptor binding and epitope diversity of V2-apex targeted HIV-1 Env immunogensR37AI150590 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Beatrice H Hahn · 2019 to 2026
$6.9M
Conformational Landscape of the HIV-1 Envelope GlycoproteinsR01AI124982 · NIAID · DANA-FARBER CANCER INST · PI SODROSKI, JOSEPH G · 2016 to 2025
$6.7M
Unlocking Envelope: A New Strategy for a Functional Cure Through Antibody-Dependent Cell-Mediated CytotoxicityR01AI129769 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PAZGIER, MARZENA ELZBIETA · 2017 to 2021
$2.3M
Enrichment of the State-1 Conformation of the HIV-1 Envelope GlycoproteinR01AI145547 · NIAID · DANA-FARBER CANCER INST · PI SODROSKI, JOSEPH G · 2019 to 2021
$2.2M
Reducing viral reservoirs by opening HIV-1 Env to antibody attackR33AI129017 · NIAID · DANA-FARBER CANCER INST · PI SODROSKI, JOSEPH G · 2019 to 2021
$1.6M
Structural Targeting of Potentially Protective gp120 Epitopes in the C1/C2 RegionR01AI116274 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PAZGIER, MARZENA ELZBIETA · 2016 to 2019
$1.5M
NIAID NIH HHS P01 AI131251NIAID NIH HHS P01 AI150471NIAID NIH HHS R01 AI116274NIAID NIH HHS R01 AI124982NIAID NIH HHS R01 AI129769NIAID NIH HHS R01 AI145547NIAID NIH HHS R33 AI129017NIAID NIH HHS R37 AI150590NIAID NIH HHS U01 AI150741NIGMS NIH HHS P01 GM056550
6 · The paper itself

Abstract

The HIV-1 envelope glycoproteins (Env) undergo conformational changes upon interaction of the gp120 exterior glycoprotein with the CD4 receptor. The gp120 inner domain topological layers facilitate the transition of Env to the CD4-bound conformation. CD4 engages gp120 by introducing its phenylalanine 43 (Phe43) in a cavity ("the Phe43 cavity") located at the interface between the inner and outer gp120 domains. Small CD4-mimetic compounds (CD4mc) can bind within the Phe43 cavity and trigger conformational changes similar to those induced by CD4. Crystal structures of CD4mc in complex with a modified CRF01_AE gp120 core revealed the importance of these gp120 inner domain layers in stabilizing the Phe43 cavity and shaping the CD4 binding site. Our studies reveal a complex interplay between the gp120 inner domain and the Phe43 cavity and generate useful information for the development of more-potent CD4mc.

Indexed as

AnimalsBinding SitesBiomimeticsCD4 AntigensCD4-Positive T-LymphocytesCell LineCrystallizationDogsHEK293 CellsHIV-1HIV Envelope Protein gp120HumansPhenylalanineProtein BindingProtein DomainsThymocytesCD4 AntigensHIV Envelope Protein gp120PhenylalanineADCCCD4CD4 binding siteCD4mcCD4 mimeticCRF01_AEEnvgp120HIV-1neutralizationPhe43 cavity

Identifiers

PMID32457241
PMCPMC7251204
OpenAlexW3029437323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.